PBH:NYSEPrestige Consumer Healthcare Inc. analysis
Data as of Sep 13, 2026 - not real-time
- Latest price
- $46.95
- Risk: medium
- 6/10Medium risk
Summary
The moving-average structure behind Prestige Consumer Healthcare Inc. is neutral at $46.95, with no clear ordering between short and long averages. The last 30 days have lost 6.0%. RSI sits at 33.7, which reads as approaching oversold, and MACD momentum is bearish. Watch $46.48 as support and $53.95 as the nearer resistance level.
Valuation screens as undervalued: a P/E of 13.2 sits below the sector average of 29.5. Consensus targets land 44.4% above where the shares trade now. Revenue is growing at 6.5% on a 15.6% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 32.4%, a beta of -0.03 and a maximum drawdown of 35.3%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Valuation screens as undervalued: a P/E of 13.2 sits below the sector average of 29.5. Consensus targets land 44.4% above where the shares trade now. Revenue is growing at 6.5% on a 15.6% profit margin.
Risk comes out at 6 of a possible 10, a elevated reading. With 30-day volatility of 32.4%, a beta of -0.03 and a maximum drawdown of 35.3%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Top market events
- In early August 2026, Prestige Consumer Healthcare reported fiscal 2027 first‑quarter revenue of US$265.
- Prestige Consumer Healthcare Inc. PBH posted first-quarter fiscal 2027 adjusted earnings per share EPS of 98 cents,...
- Prestige Consumer Healthcare NYSE:PBH closed two acquisitions within three weeks this summer, adding roughly $240...
Market outlook
Short term
< 1 yearNeutral
Model confidence1/101 out of 10
Key factors
- Trading below the 200-day average of 56.58
- MACD momentum is negative
- 30-day price change of -6.0%
Medium term
1–3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- P/E of 13.2 versus sector average of 29.5
- Trading below the 200-day average of 56.58
- Analyst targets imply +44.4% versus the current price
Long term
> 3 yearsPositive
Model confidence5/105 out of 10
Key factors
- P/E of 13.2 versus sector average of 29.5
- Analyst targets imply +44.4% versus the current price
- Profit margin of 15.6% is healthy
Key metrics
Financial health
Revenue Growth6.50%
Profit Margin15.57%
P/E Ratio13.2
ROE9.12%
ROA4.58%
Debt/Equity107.86
P/B Ratio1.2
Op. Cash Flow$249.4M
Free Cash Flow$147.9M
Industry P/E29.5
Technical analysis
TrendNeutral
RSI33.7
Support$46.48
Resistance$53.95
MA 20$50.98
MA 50$50.74
MA 200$56.58
MACDBearish
VolumeStable
Fear & Greed Index93.14
Valuation
Fair Value$9.06
Target Price$67.80
Upside/Downside44.41%
GradeUndervalued
TypeBlend
Risk assessment
Beta-0.03
Volatility32.42%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.